- Cardiol Therapeutics (TSX:CRDL) has announced results from one of its collaborating research centers demonstrating the effects of cannabidiol in a model of heart failure
- The company’s lead drug candidate CardiolRx is currently in a Phase II clinical trial for recurrent pericarditis and acute myocarditis
- The studies were presented by researchers from Mexico at the American College of Cardiology’s 72nd Annual Scientific Session with the World Congress of Cardiology
- Shares of Cardiol Therapeutics are up 1.41 per cent to C$0.72 as of 1:47 p.m. EST on Tuesday
Cardiol Therapeutics (CRDL) is making a splash in the heart failure market through its lead cannabidiol product.
In a press release on Tuesday, the Oakville, Ontario-based life science company released study results for its lead product candidate CardiolRx, which is currently being evaluated in a model with heart failure.
CardiolRx is also currently in Phase II clinical trials for recurrent pericarditis and acute myocarditis, which are both heart-related inflammation conditions.
Cardiol Therapeutics said the recent studies were presented by researchers from the Instituto Tecnologico y de Estudios Superiores de Monterrey from Mexico at the American College of Cardiology’s 72nd Annual Scientific Session, with the World Congress of Cardiology.
“The beneficial effects of cannabidiol in a pre-clinical model of heart failure are of great interest and importance in support of our ARCHER trial, which is investigating the recovery of cardiac function in patients with myocarditis,” Dr. Andrew Hamer, Cardiol’s Chief Medical Officer and Head of Research and Development, said in a press release.
What is CardiolRx?
At present, CardiolRx is being evaluated in a Phase II multi-national study called the ARCHER trial to evaluate the drug’s safety and tolerability and its impact on myocardial discovery in patients with acute myocarditis.
The trial anticipates enrolling 100 patients at cardiac centers across North America, Europe, Latin America and Israel.
The company received an investigational new drug application authorization from the US Food and Drug Administration (FDA) in May 2022 to begin a Phase II open-label study to evaluate the tolerance and safety of CardiolRX in patients with recurrent pericarditis. The study’s objective is to assess the improvement in objective measures of the disease.
Cardiol Therapeutics is also planning to pursue developing CardiolRX as an orphan drug to treat acute myocarditis and recurrent pericarditis.
Shares of Cardiol Therapeutics (CRDL) are up 1.41 per cent to C$0.72 as of 1:47 p.m. EST on Tuesday